Drug intelligence / Profile preview

AD-227A + AD-227C

Development stage: Unknown
Lead developer: Addpharma
Administration: Oral

Overview

AD-227A + AD-227C is a combination investigational therapy comprising the code-named drug candidates AD-227A and AD-227C, developed for the treatment of essential hypertension. The drug pair is being evaluated in clinical trials, primarily for efficacy and safety as a co-administration regimen, and is sponsored by Addpharma. Detailed mechanisms of action, molecular targets, and pharmacologic class for AD-227A and AD-227C are not specified in public sources; thus, their precise biological actions remain uncharacterized in the available literature.

Beyond the preview

Go deeper on AD-227A + AD-227C.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AD-227A + AD-227C.

Explore the full profile